📰 Colitis Organization News
Page 2 - Colitis Organization News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Colitis Organization. Real-time updates on events, politics, business and more.
April 14, 2023
The FDA cited manufacturing concerns in their letter for the potential ulcerative colitis treatment.
March 4, 2023
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA® (ustekinumab)...
March 3, 2023
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced additional results from in vitro MODIF-Y studies, which continue to...
March 3, 2023
Patients with IBD who concurrently use cannabis show a highly significant reduction in inpatient mortality and hospital length of stay and around 25% drop in hospitalization costs.
February 27, 2023
Six presentations demonstrate Galapagos' commitment to the inflammatory bowel disease (IBD) communityNew analyses from Phase 3 SELECTION and SELECTION long-term extension (LTE) studies of Jyseleca® (filgotinib
February 27, 2023
Investegate announcements from Galapagos NV, Galapagos to present new data from long-term extension study of filgotinib in ulcerative colitis at annual ECCO congress 2023
January 31, 2023
Stelara treatment for severely active Crohn's disease resulted in high clinical response and clinical remission rates, according to 16-week trial results.
January 20, 2023
Investigating the association between childhood and adulthood tobacco smoking exposure with ulcerative colitis and Crohn’s disease in Qatar.
June 20, 2022
The findings of the current study may provide evidence-based information for Chinese gastroenterologists to treat IBD more effectively in the future.
June 9, 2022
Strategic collaboration to further develop olamkicept highlights Ferring's continued commitment to innovation in gastroenterology and inflammatory bowel disease. Olamkicept is the first and